Drug Shows First Potential Treatment For Common Anaemia
Facebook Twitter google+ RSS Feed

Drug Shows First Potential Treatment For Common Anaemia

Friday, 29 August 2014, 09:57 Hrs
cmt right
Comment Right
cmt right
cmt right
Printer Print Email Email

WASHINGTON: An experimental drug designed to help regulate the blood's iron supply shows promise as a viable first treatment for anaemia of inflammation.

The present treatment strategy for anaemia of inflammation targets the underlying disease or infection.

But recent research has sought to explore additional options for patients whose inflammation is difficult to control or when the cause of inflammation is unknown.

Hepcidin, which is the principal regulator of iron, has drawn a lot of attention from researchers developing novel therapies for blood disorders.

One hepcidin inhibitor, called lexaptepid pegol (lexaptepid) has shown efficacy in treating anaemia of inflammation in animal studies and now researchers have tried the experiment in human beings.

Lexaptepid inactivates hepcidin, thereby maintaining the transport of iron to the bloodstream.

"It is quite encouraging that lexaptepid helped maintain appropriate levels of iron in the bloodstream of healthy volunteers without compromising the immune response," said Lucas van Eijk of Radboud University Medical Center in Nijmegen, the Netherlands.

The results appeared in Blood Journal of American Society of Hematology.

Read More: Celebrities Replaced By Products For Endorsements and The 10 Most World-Changing Ads

Source: IANS
Experts on SiliconIndia
Santhosh  K
Sr. Soft. Engg.
Oracle India
Nehal Vyas
Sr. Team Lead
Cyberoam Tech.
Rani Malli
Sr. Director
Sr. Executive
Vijay Balkrishna Konduskar
Business Consultant
Imans Web Tech
Dr L P  Sharma
Technical Director
Reena Khanna
Dellas  Asse
sys-network admin
Computer Station
Write your comment now
Submit Reset